VX-770 Shows Hope for CF Patients.

The Cystic Fibrosis Foundation and Vertex Pharmaceuticals announced today that VX-770, an oral medicine in development that targets the defective protein that causes cystic fibrosis, showed promising results in a Phase 3 clinical trial.

Read the article using the link below.

http://www.cff.org/aboutCFFoundation/NewsEvents/2011NewsArchive/2-23-Phase-3-Study-VX-770-Shows-Positive-Results.cfm

Pulmozyme Access Solutions

Pulmozyme Access Solutions Co-Pay Card Program by Genentech

www.pulmozymecopaycard.com

This is a program designed to help you stay connected to the medicine you need through co-pay support.

Eligible Pulmozyme patients should:

• Be over the age of 18 or have a legal guardian over the age of 18 with commercial insurance.
• Have a coinsurance of more than $30 per month.

If you are having trouble with the cost of co-pays from your Pulmozyme, then you should check into this program.

CFRI Presents Getting A Good Night's Sleep

Register early to view Getting A Good Night's Sleep on Tuesday, January 11, 2011 (6pm PST/7pm MST/8pm CST/9pm EST) online LIVE.

This free presentation is a part of CFRI and Stanford's CF Discovery Series. Nanci Yuan, M.D., will answer questions about CF-impacted sleeping problems and will discuss ways to healthier, more effective sleep.

To register, you must create an account on UStream and search for CFRI LIVE. Click here for registration page. To attend the event in person, click here. Special thanks to Genentech for sponsoring this event! http://www.cfri.org/home.shtml